Method and composition for altering a B cell mediated pathology

Details Method and composition for altering a B cell mediated pathology Method and composition for altering a B cell mediated pathology

2005-06-28

2005-06-28

Gambel, Phillip (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S130100, C424S178100, C435S069100, C435S071100, C435S320100, C435S348000, C514S885000

Reexamination Certificate

active

06911204

ABSTRACT:
The present invention provides methods and compositions for altering a B cell mediated malignancy in a patient. These methods comprise administering a composition comprising at least one or two chimeric proteins. Each chimeric protein comprises at least a portion of either the VHor VLregion of the Id protein of the B cells associated with the B cell mediated malignancy, and an immunoglobulin constant region. The genes encoding VHor VLregions are isolated and inserted into an expression vector encoding immunoglobulin constant regions. The chimeric proteins are expressed in insect cell lines. The purified chimeric proteins are conjugated to an immunogenic carrier protein. The conjugates comprising the chimeric Id protein(s) are administered to such a patient, with or without a cytokine or chemokine, the chimeric protein induces immune responses to alter the B cell mediated malignancy.

REFERENCES:
patent: 3969287 (1976-07-01), Jaworek et al.
patent: 4195128 (1980-03-01), Hildebrand et al.
patent: 4229537 (1980-10-01), Hodgins et al.
patent: 4247642 (1981-01-01), Hirohara et al.
patent: 4330440 (1982-05-01), Ayers et al.
patent: 4338397 (1982-07-01), Gilbert et al.
patent: 4399216 (1983-08-01), Axel et al.
patent: 4444878 (1984-04-01), Paulus
patent: 4468464 (1984-08-01), Cohen et al.
patent: 4512922 (1985-04-01), Jones et al.
patent: 4634665 (1987-01-01), Axel et al.
patent: 4661586 (1987-04-01), Levy et al.
patent: 4704362 (1987-11-01), Itakura et al.
patent: 4745051 (1988-05-01), Smith et al.
patent: 4816249 (1989-03-01), Levy et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 4840896 (1989-06-01), Reddy et al.
patent: 5053224 (1991-10-01), Koprowski et al.
patent: 5078996 (1992-01-01), Conlon, III et al.
patent: 5122464 (1992-06-01), Wilson et al.
patent: 5162111 (1992-11-01), Grabstein et al.
patent: 5179017 (1993-01-01), Axel et al.
patent: 5229496 (1993-07-01), Deeley et al.
patent: 5254534 (1993-10-01), Tachibana et al.
patent: 5281699 (1994-01-01), Chang
patent: 5334379 (1994-08-01), Pillai et al.
patent: 5478556 (1995-12-01), Elliott et al.
patent: 5580561 (1996-12-01), Cercek et al.
patent: 5602007 (1997-02-01), Dunn et al.
patent: 5612035 (1997-03-01), Howell et al.
patent: 5650150 (1997-07-01), Gillies
patent: 5679347 (1997-10-01), Porcelli et al.
patent: 5679356 (1997-10-01), Bonnem et al.
patent: 5728377 (1998-03-01), Sarris et al.
patent: 5789206 (1998-08-01), Tavtigian et al.
patent: 5792445 (1998-08-01), Tournier et al.
patent: 5861164 (1999-01-01), Howell et al.
patent: 5891429 (1999-04-01), Clark et al.
patent: 5891432 (1999-04-01), Hoo
patent: 5895646 (1999-04-01), Wang
patent: 5900238 (1999-05-01), Gombotz et al.
patent: 5904920 (1999-05-01), Dranoff et al.
patent: 5929196 (1999-07-01), Kissel et al.
patent: 5942221 (1999-08-01), Clark et al.
patent: 5942253 (1999-08-01), Gombotz et al.
patent: 5972334 (1999-10-01), Denney, Jr.
patent: 5980911 (1999-11-01), Corner et al.
patent: 6063905 (2000-05-01), Capra et al.
patent: 6080409 (2000-06-01), Laus et al.
patent: 6083521 (2000-07-01), Acemoglu et al.
patent: 6083703 (2000-07-01), Wang et al.
patent: 6087110 (2000-07-01), Wang et al.
patent: 6096313 (2000-08-01), Jäger et al.
patent: 6099846 (2000-08-01), Levy et al.
patent: 6120807 (2000-09-01), Gombotz et al.
patent: 6274175 (2001-08-01), Gombotz et al.
patent: 6309632 (2001-10-01), Agosti
patent: 6312690 (2001-11-01), Edelman et al.
patent: 6312718 (2001-11-01), Popescu et al.
patent: 6331415 (2001-12-01), Cabilly et al.
patent: 6338953 (2002-01-01), Boyce et al.
patent: 6338962 (2002-01-01), Boyce
patent: 6342216 (2002-01-01), Fidler et al.
patent: 6348449 (2002-02-01), Weiner et al.
patent: 6361948 (2002-03-01), Tricoli et al.
patent: 2139756 (1994-01-01), None
patent: 0351876 (1990-01-01), None
patent: 0370656 (1990-05-01), None
patent: 0183350 (1992-01-01), None
patent: 0382381 (1993-05-01), None
patent: 0326149 (1993-08-01), None
patent: 0874054 (1998-03-01), None
patent: 2658432 (1991-08-01), None
patent: 62089621 (1987-04-01), None
patent: 62230729 (1987-09-01), None
patent: 64-027492 (1989-01-01), None
patent: 1-193227 (1989-08-01), None
patent: 02-002390 (1990-01-01), None
patent: 02-076820 (1990-03-01), None
patent: 10-295379 (1998-11-01), None
patent: 2000-256209 (2000-09-01), None
patent: 88/00832 (1988-02-01), None
patent: 91/05046 (1991-04-01), None
patent: WO 92/08495 (1992-05-01), None
patent: 93/20835 (1993-10-01), None
patent: 94/01133 (1994-01-01), None
patent: WO96/07740 (1996-03-01), None
patent: 96/10395 (1996-04-01), None
patent: 97/13502 (1997-04-01), None
patent: WO 97/29769 (1997-08-01), None
patent: WO 97/35008 (1997-09-01), None
patent: 98/16246 (1998-04-01), None
patent: WO 98/30577 (1998-07-01), None
patent: WO 99/29732 (1999-06-01), None
patent: WO 99/46392 (1999-09-01), None
patent: WO 99/52562 (1999-10-01), None
patent: WO 99/57981 (1999-11-01), None
patent: WO 00/06733 (2000-02-01), None
patent: WO 00/47228 (2000-08-01), None
Tan et al. Biotechnol. Appl. Biochem. 1999; 30:59-64.
Mroczkowski et al. J. Biol. Chem. 1994; 269(18):13522-13528.
Chapter 139 of The Merck Manual of Diagnosis and Therapy, eds. Beers M.H. and Berkow R, Seventeenth Edition, 1999, Merck Research Laboratories, Whitehouse Station, N.J., pp. 955-962.
Benvenuti, F., et al., “Anti-Idiotypic DNA Vaccines for Lymphoma Immunotherapy Require the Presence of Both Variable Region Genes for Tumor Protection”Gene Therapy7(7):605-611 (2000).
Selmayr, M., et al., “B-Cell Lymphoma Idiotypes Chimerized by Gene Targeting Can Induce Tumor Immunity,”Cancer Gene Therapy7(3): 501-506 (2000).
Veelken, H., et al., “Rapid Expression Cloning of B Cell Lymphoma-Derived Immunoglobulin Genes for Anti-Idiotypic Vaccination and Functional Analyses of Fab-Fragments,”Blood90(10): 515A (1997).
Accolla, et al., “Monoclonal antibodies specific for carcinoembryonic antigen and produced by two hybrid cell lines,”Proc. Natl. Acad. Sci. USA.,77(1)563-566 (1980).
Adams, et al., “Molecular Cloning of Mouse Immunoglobulin Heavy Chain Messenger Ribonucleic Acids Coding for, μ, α, γ1, γ2a, and γ3 Chains,”Biochemistry,19:2711-2719 (1980).
Advani, et al., “Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as an Adjunct to Autologous Hemopoietic Stem Cell Transplantation for Lymphoma,”Annals of Internal Medicine,116(3):183-189 (1992).
Amster, “Synthesis of part of a mouse immunoglobulin light chain in a bacterial clone,”Nucleic Acids Research,8(9):2055-2065 (1980).
Azuma, et al., “Stimulation of Host-Defense Mechanism with Synthetic Adjuvants and Recombinant Cytokines Against Viral Infection in Mice,” in Friedman, et al., ed.,Microbial Infections,Plenum Press, New York, pp. 253-263 (1992).
Backman and Ptashne, “Maximizing Gene Expression on a Plasmid Using Recombinationin Vitro,”Cell,13:65-71 (1978).
Baltimore, et al., “Expression of the Abelson Murine Leukemia Virus Genome and of Transfected κ Immunoglobulin Genes,”Journal of Cellular Biochemistry,12thAnnual UCLA Symposia Abstracts, Suppl. 7A, Abstract 0224 (1983).
Banerji, et al., “Expression of a β-Globin Gene Is Enhanced by Remote SV40 DNA Sequences,”Cell,27:299-308 (1981).
Bendandi, “Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma,”Expert Rev. Anticancer Ther.,1(1):65-72 (2001).
Bernard, et al., “Sequences of Mouse Immunoglobulin Light Chain Genes before and after Somatic Changes,”Cell15:1133-1144 (1978).
Bixler and Pillai, “Augmentation by Interleukins of the Antibody Response to a Conjugate Vaccine AgainstHaemophilus influenzaB,” in Atassi, ed.,Immunobiology of Proteins and Peptides VI,Plenum Press, New York, pp. 185-190 (1991).
Bonnem, Alpha Interferon: The Potential Drug of Adjuvant Therapy: Past Achievements and Future Challenges,Eur. J. Cancer,27(Suppl. 4):S2-S7 (1991).
Bonnem, “Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF): Biology

Affiliated with

Also associated with

Rating

Method and composition for altering a B cell mediated pathology does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method and composition for altering a B cell mediated pathology, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and composition for altering a B cell mediated pathology will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3459287